pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Nucala
drug
save

mepolizumab

Marketedupdated 3mo ago
by GlaxoSmithKline LLC
Approved
community read0 votes

indications

investigational
Asthma

all catalysts(0)

nothing on the calendar yet

Trials studying mepolizumab

  • phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)active not recruitingn=163
  • phase3Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trialcompletedn=238
  • —NUCALA® Special Drug Use Investigation (EGPA, Long-term)completedn=4,115
  • phase3Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.active not recruitingn=140
  • —Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthmacompletedn=106
  • EP1The Role of IL5 in Epithelial Cell Integrityrecruitingn=8
  • phase3A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)recruitingn=166
  • phase3Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)completedn=16
more trials →

News(1)

  • A COPD drug from China draws $115M in venture funding
    Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
    biopharma_dive · 6d ago
brand
Nucala
generic
mepolizumab
indication
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 16m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?